Reading the tape
NASDAQ: ORIC
ORIC Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market Cap
$925.80M
52w High
$14.93
52w Low
$4.52
P/E
-7.20
Volume
733.10K
Outstanding Shares
100.36M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
1Y Price: 63.51%FCF (TTM): 4.5%
What changed
The stock rose 63.51% over the last year. Free cash flow grew 4.5% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States.
CEOJacob Chacko
SectorHealthcare
IndustryBiotechnology
Employees122
IPO dateApr 24, 2020
Valuation
Forward P/E—
EV/EBITDA-5.33
Enterprise value$684.04M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-33.68%▲35.94%vs FY2024
Analyst consensus
RatingBuy
Target price$21.75▲135.77%
10
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 11, 2026
Q3 FY26 · EPS est -$0.33 · Revenue est —
View